Yttrium86QualityChecker

Utility description: Yttrium-86

Yttrium-86 Quality Checker — Yttrium-86 for PET Dosimetry (Theranostics with Y-90)

ℹ️  Utility checks critical parameters of Yttrium-86:
    • Radionuclidic purity (≥99.0%)
    • Yttrium-87 impurity (≤1.0%)
    • Yttrium-88 impurity (≤0.01%) — CRITICAL!
    • Strontium-82 impurity (≤0.001%)
    • Radiochemical purity (≥95%, DOTA complex)
    • Free yttrium (≤5%)
    • pH, endotoxins, sterility, heavy metals

⚠️  CRITICAL: Yttrium-88 (T½=106 days) creates long-term waste issues.
    Y-86 is used for dose calculation before Y-90 therapy.

Usage:
  Yttrium86QualityChecker.exe                            → demo mode (console output)
  Yttrium86QualityChecker.exe input.csv output.json      → evaluate your data

Input format:
BatchNumber,TotalActivityMBq,RadionuclidicPurityPercent,Yttrium87ImpurityPercent,Yttrium88ImpurityPercent,Strontium82ImpurityPercent,RadiochemicalPurityPercent,FreeYttriumPercent,pH,EndotoxinsEU,SterilityTest,HeavyMetalsPPM,ProductType

Example (sterility: 0=sterile, 1=contaminated):
  Y86-DOTA-2026-001,50.0,99.5,0.4,0.005,0.0005,98.0,2.0,5.5,30.0,0,2,DOTA-Peptide

Supported product types:
• DOTA-Peptide — peptides for Y-90 therapy dosimetry
• Antibody — antibodies for immuno-PET and dosimetry
• FreeIon — biodistribution studies

— WHY IS THIS NEEDED?
Yttrium-86 (T½=14.7 h) is a positron-emitting isotope for PET:
• Chemically identical to therapeutic Yttrium-90 (beta-emitter)
• Allows precise dosimetry before Y-90 therapy (personalized medicine)
• Used for imaging drug distribution (peptides, antibodies)
• Produced in cyclotron (Sr-86(p,n)Y-86)

⚠️  CRITICAL:
• Radionuclidic purity ≥99.0% — presence of other isotopes is unacceptable.
• Yttrium-88 (T½=106.6 days) impurity ≤0.01% — CRITICAL PARAMETER. Long-lived isotope that makes radioactive waste hazardous for many years. Even trace amounts are strictly regulated.
• Yttrium-87 (T½=3.35 days) impurity ≤1.0% — Creates additional radiation burden without diagnostic benefit.
• Strontium-82 (T½=25 days) impurity ≤0.001% — Parent isotope, accumulates in bones. Strict control.
• Radiochemical purity ≥95% — Yttrium forms stable complexes with macrocyclic chelators (DOTA). High RCP ensures in vivo stability.
• Free yttrium ≤5% — Ionic yttrium accumulates in liver and bones, distorting dosimetry data.
• Heavy metals ≤10 ppm — Compete for chelator, reducing specific activity.
• pH 4.5–7.5, Endotoxins ≤175 EU/vial, Sterility — standard safety requirements.

Key features:
• Strict control of long-lived impurities (Y-88, Sr-82)
• Assessment of suitability for theranostic application (pair with Y-90)
• Heavy metal control
• Support for various bioconjugates

Critical parameters:
• Radionuclidic purity: ≥99.0%
• Y-88 impurity: ≤0.01% (CRITICAL!)
• Y-87 impurity: ≤1.0%
• Sr-82 impurity: ≤0.001%
• Radiochemical purity: ≥95.0%
• Free yttrium: ≤5.0%
• Heavy metals: ≤10 ppm
• pH: 4.5–7.5
• Endotoxins: ≤175 EU/vial
• Sterility: no microbial growth

💡 Usage tips:
1. Production of Y-86 requires highly enriched Sr-86 targets to minimize Y-88 formation.
2. Labeling DOTA-peptides requires heating (95°C, 15-20 min).
3. Presence of heavy metals in buffer or precursor sharply reduces specific activity. Use ultra-pure reagents.
4. Y-86 has a complex decay spectrum (positrons + high-energy gamma quanta), requiring correction for quantitative PET imaging.

⚠️ Note: Y-86 allows transition from "standard dose" Y-90 to "personalized dose" calculated based on actual biodistribution in a specific patient. However, the problem of long-lived impurities (Y-88) is the main limitation for its widespread clinical implementation.